Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One of these days
It was... for a brief period. Still expecting good things here eventually.
Whoa, some really big buys coming thru! 354k so far.
Hmmmmmmmmmmmm - interesting
Hey, look! Someone bought 100,000 at .07. Then, after a couple of smaller trades, another 100,000 at .074. I wonder if DGEN has been discovered...
If only it translated into some buying
One thing I can say for these guys - they write a very nice press release, packed with good information.
Impressive roster of people with "Dr." in front of their names, too.
Deltagen Reports 2009 Fourth Quarter and Full-Year Financial Results
Mar 29, 2010 6:00:00 PM
Copyright Business Wire 2010
SAN MATEO, Calif.--(BUSINESS WIRE)-- Deltagen, Inc. (Pink Sheets:DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months and year ended December 31, 2009.
Revenues: The Company's consolidated revenues for the three months and year ended December 31, 2009 totaled $0.352 million and $1.357 million, respectively. The revenues in the fourth quarter were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company's DeltaOneTM program. Cumulative revenues for the third and fourth quarters of 2009 ($0.811 million) increased 49% over cumulative revenues for the first and second quarters of 2009 ($0.546 million). The increase in revenues in the second half of 2009 was associated with a rebound in deal flow following significantly decreased deal flow during the fourth quarter of 2008 and the first quarter of 2009.
Interest Income: The Company had interest income of $0.002 million and $0.016 million for the three months and year ended December 31, 2009, respectively.
Expenses: Total consolidated expenses for the three months and year ended December 31, 2009 were $0.705 million and $2.060 million, respectively. The expenses in the fourth quarter (and full-year 2009) were attributable primarily to labor costs and other general and administrative expenses, including $0.083 million ($0.408 million) in royalty and commission expenses, expenses of $0.293 million ($0.430 million) relating to the Company's December 10, 2009 acquisition and operation of Benten BioServices, Inc. ("Benten Expenses"), and non-recurring expenses of $0.116 million ($0.272 million) associated with the prosecution and issuance of patents licensed exclusively to Xenopharm, Inc. ("Xenopharm"), a wholly-owned subsidiary of the Company. In addition, the total expenses in the fourth quarter of 2009 included $0.057 million in non-cash, stock-based compensation expenses relating to stock options granted by the Company on December 21, 2009 in accordance with Statement of Financial Standards (SFAS 123R). As of December 31, 2009, the Company had paid to Lexicon Pharmaceuticals, Inc. ("Lexicon") an aggregate total of $4.803 million in royalty payments pursuant to a March 2005 settlement agreement between Lexicon and the Company. Under the settlement, the maximum, aggregate amount of royalty payments due to Lexicon is $6 million. Accordingly, up to $1.197 million in contingent royalty payments remained owed to Lexicon as of December 31, 2009.
Net Losses: Consolidated net losses before provision for income taxes for the three months and year ended December 31, 2009 were $0.350 million and $0.687, respectively. Excluding Benten Expenses, net losses before provision for income taxes for the three months and year ended December 31, 2009 would have been $0.057 million and $0.257 million.
Cash, Cash Equivalents and Accounts Receivable: As of December 31, 2009, the Company had $5.704 million in consolidated cash and cash equivalents (compared to $5.084 million as of December 31, 2008) and $0.131 million in accounts receivable.
Major Events during 2009 and Subsequent Events:
Acquisition of Benten BioServices: On December 10, 2009, the Company announced its acquisition of Benten BioServices, Inc. ("Benten"), an emerging Pennsylvania-based contract services organization dedicated to the provision of regulatory-compliant services to support the development and commercialization of biopharmaceutical products. Benten's services are designed to address specific requirements for critical stages in product development, including biosafety testing, raw materials testing, assay and process validation services, cell banking and characterization services, and technology platform-specific R&D support and consulting services.
Deltagen issued 9,126,085 shares of common stock to the former Benten shareholders in exchange for all of Benten's outstanding equity securities. Penn Venture Partners, L.P. and Life Sciences Greenhouse of Central Pennsylvania invested $1,250,000 and $250,000, respectively, in the combined company. The transaction valued Deltagen at $7,000,000 prior to the transaction and the combined company at $8,500,000 after the transaction. With a total of 51,714,483 shares outstanding after the closing, the transaction valuation represented approximately $0.164 per Deltagen share. As a result of the transaction, the former Benten shareholders own 17.65% of Deltagen's outstanding common stock.
Benten plans to lease facilities and operate in Pennsylvania as a wholly-owned subsidiary of Deltagen. Benten's services will be offered worldwide to biopharmaceutical companies, emerging biotechs, government agencies and universities involved in the development of biologicals, recombinant proteins, monoclonal antibodies, cell therapeutics, vaccines and biological devices. Additional details relating to the acquisition and business of Benten are provided in the Company's December 10, 2009 press release.
The Company has entered into a non-binding letter of intent with respect to the prospective leasing of facilities for Benten's operations to be located in Pennsylvania.
Issuance of Stock Options: In connection with the acquisition of Benten, the Company's Board of Directors approved a grant of stock options to the officers and directors of the combined company. On December 21, 2009, the Company granted the following options to purchase shares of the Company's common stock at an exercise price of $0.075 per share:
Paula MacDonald - 2,100,000 incentive stock options ("ISOs")
Dr. Robert Driscoll - 825,000 ISOs
Dr. Winston Thomas - 425,000 ISOs
Dr. Harvey Schlesinger - 300,000 ISOs
Dr. Constantine Anagnostopoulos - 150,000 nonstatutory stock options ("NSOs")
Dr. William Scott - 125,000 NSOs
Martin Hernon - 125,000 NSOs
Thomas Penn - 125,000 NSOs
The four-year vesting schedule of the ISOs is as follows: 25% vested on the grant date and, beginning on the first anniversary of the grant date, equal monthly vesting over the subsequent three-year period. The three-year vesting schedule of the NSOs is as follows: 25% vested on the grant date and, beginning on the first anniversary of the grant date, equal monthly vesting over the subsequent two-year period.
Xenopharm Patents Issued: Xenopharm is an exclusive licensee under certain technologies relating to the metabolism of foreign compounds, known as xenobiotics, invented by Professor Christopher Liddle et al. and assigned to the University of Sydney ("Sydney"). Three Sydney patents were newly granted and issued in December 2009 and January 2010: United States Patent No. 7,638,614 (December 29, 2009); European Patent No. 1,082,437 (December 16, 2009); and Japanese Patent No. 4,446,603 (January 29, 2010).
The patents cover technologies relating to modulating or effecting gene expression and/or formation of human cytochrome P450 CYP3A4 enzyme, an enzyme expressed primarily in the human liver. The CYP3A4-related technologies provide a system for screening potential new drug compounds for susceptibility to metabolic action in human patients and for generally studying the metabolism of xenobiotics in humans, including drug clearance, potential drug toxicity and drug-drug interactions.
The unaudited consolidated financial statements for the fourth quarter and year of 2009, accompanying notes, and Management's Discussion and Analysis of Financial Conditions and Results of Operations for such period will be posted on Deltagen's website (www.deltagen.com).
About Deltagen
Deltagen, Inc. is a leading provider of drug discovery tools to the biopharmaceutical industry. Deltagen offers access to its extensive inventory of knockout mouse lines and related phenotypic data, which enhance the efficiency of target validation and drug discovery. In addition, Deltagen offers target validation data in the areas of immunology and metabolic diseases. Deltagen's products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Inc. and Pfizer Inc. For more information on Deltagen, visit the Company's website at www.deltagen.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about Deltagen's future revenues, cash flows and operating results, third-party royalty obligations and third-party licenses and intellectual property, Benten's business plans, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Deltagen's ability to achieve its operational objectives and revenue projections, that may cause Deltagen's actual results to be materially different from any future results expressed or implied by such forward-looking statements. There are no assurances that the Company will declare any future dividends. Information identifying such important risk factors is contained in "Management's Discussion and Analysis of Financial Conditions and Results of Operations", which can be found at Deltagen's website at www.deltagen.com. Deltagen undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
DELTAGEN, INC.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)
Consolidated Balance Sheet
As of 12/31/09
Unaudited
(In Thousands) 12/31/09
Consolidated
Assets
Current assets:
Cash and cash equivalents 5,704
Accounts receivable, net 131
Prepaids, Deposits and Tax Assets 54
Total current assets 5,889
Property and equipment, net 62
Goodwill 224
Non-current portion of deferred tax assets 1,586
Total assets 7,761
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable 223
Accrued expenses 31
Total liabilities 254
Stockholders' equity:
Common stock 39
Treasury Stock (867)
Additional paid-in capital 230,615
Retained Earnings (222,683)
Foreign currency translation adjustment 402
Total stockholders' equity 7,507
Total liabilities and stockholders' equity 7,761
DELTAGEN, INC.
CONSOLIDATED INCOME STATEMENT
(UNAUDITED)
Consolidated Income Statements and
Statements of Retained Earnings
For Quarter ended 12/31/09 & Full Year 2009
Unaudited Unaudited
(In Thousands) 12/31/09 FY2009
Consolidated Consolidated
Revenue 352 1,357
Royalty and Commission Costs 83 407
Other Operating Costs 622 1,653
Income From Operations (352) (703)
Interest Income 2 16
Loss on disposal of assets - -
Total Other Income 2 16
Income before provision for income taxes (350) (687)
Provision for income taxes
Current income tax expense - -
Deferred income tax expense - -
Adjustment for valuation allowance - -
Total income tax expense - -
Net Income (Loss) (350) (687)
Retained earnings at beginning of period (222,333) (221,996)
Retained earnings at end of period (222,683) (222,683)
DELTAGEN, INC.
CONSOLIDATED CASH FLOW
(UNAUDITED)
Consolidated Cash Flows
For Quarter ended 12/31/09 & Full Year 2009 Unaudited Unaudited
12/31/09 FY2009
(Dollars In Thousands) Consolidated Consolidated
Cash flows from operating activities:
Net Income (Loss) (350) (687)
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation 4 17
Stock-based compensation expense 57 57
Loss on disposal of fixed assets - -
(Increase)/Decrease in operating assets
Accounts receivable 65 284
Prepaids, deposits and tax assets 42 581
Purchase of assets - (21)
Deferred tax assets - (586)
Increase/(Decrease) in operating liabilities
Accounts payable 36 (6)
Accrued expenses (42) (306)
Change in goodwill (224) (224)
Stock issuance for Benten BioServices acquisition 1,497 1,497
Dividends Paid - -
Net Increase/(Decrease) in cash 1,084 606
Effect of foreign exchange rate change on cash and - 14
cash equivalents
Cash and cash equivalents, at beginning of period 4,620 5,084
Cash and cash equivalents, at end of period 5,704 5,704
Source: Deltagen, Inc.
----------------------------------------------
Deltagen
Inc.
Robert J. Driscoll
650-345-7601
President & CEO
Hey everyone, wake up! New market maker CSTI has arrived and is bidding .07. Most likely his buyer is the one who cleared out the .07 offer. Volume 77,052 for the day thus far. NITE is gone from the box.
Maybe we're almost ready to get moving here.
Start with 260 Joules, CLEAR !!!! Zzz z z
Yeah, I know. Get the defibrillator. I still think it'll move eventually, but who knows when....
What is up with this duck, somebody start the engines !!!
If we keep this up we'll be in Breakout Boards! (by 2013)
Thanks guys. I feel a little less lonely now.
Here, invested and waiting
Here! Sorry, like to follow Walker around, he has been very helpful to this newbie. But I'm still here and will be looking at DGEN.
Eventually - yes
Nice to see you guys.
I guess nothing has changed with DGEN, fundamentally, but we're all occupied with our CTDH, NEIK, GRNO, CDIV, HSTC and other runners. I still believe that DGEN is going to be a big winner eventually.
Zzzzzzzzzzzzzzzz.
Oh yeah, right, I own some of this stock.
Roll call!
satelliteguy?
Present!
ksuave?
Walker?
finbar99?
I took a look at VRMLQ and I passed. F! Still hurts. Shows what I know.
Yes, understood, the valuation was based largely on the cash.
Anything remotely resembling VRMLQ would be nice.
>>people who have inside knowledge of the company believed that the stock was worth .16
again, they were pretty much just buying into the cash - but bringing some sweat equity and a unique oppty in exchange. I'd love nothing more than to see Driscol repeat his prior performance from 6 years back. I'm somewhat jaded against him as I had higher hopes for my cheap shares - I was looking for something more along the lines of VRMLQ - that may be more my fault than his - I've kept most of them all these years for a reason, above and beyond them being free.
The ones that bought in were associated both with the Charles River guys and DGEN - the main one sits on DGEN's board. They were basically buying in at cash value of DGEN - which is fine with me. I would have been very happy at this point to just get the cash value back, but that wasn't going to happen - and I do believe in the underlying IP - which is why when I was down like 80% on a buttload of shares I bought even more at a penny - I still remember the HS! moment when I got filled - thinking I had surely lost my mind. I learned how to go with my gut that day.
I'm ready for Driscol and the rest of the board to earn their keep - they haven't done much for me lately. If I wasn't going to get cash value back, I think this may be best oppty they could have taken - but I think much will depend on the politics of pharma that is beyond their control. The biggest reason they filed bk in the first place was that all the pharmas merged - so instead of having a dozen customers that really needed to pay 25 mm for access to the mice, they found themselves with something less than 6.
Very nice report - much appreciated. I just bought DGEN the week before the press releases so I didn't have very much of that background info, but as Walker said, people who have inside knowledge of the company believed that the stock was worth .16. Even if they were off by a few cents, I continue to believe that this thing was a good buy at .10, then .11, then .08, then .061, and I'm content to wait for them to give us some sort of update on their business.
It looks to me like the selling has mostly dried up, but when the stock price gets back up to the .10 area that will again become enticing to those who have shares at .05 and lower. We'll just have to chew through them.
Thanks for the info. - so what do you think the chances are here for success and a much higher shareprice? Seems like the 2 funds that bought in on the Benten deal valued the company at .162 per share b/c thatis what they paid for their shares.
I talked with Driscol right after the deal was announced. I started buying into DGEN a few months after they filed for bankruptcy many many moons ago. Started buying it at 10 cents, bot more at .08 and a bunch more at .05, loaded up the truck at .03 and then got filled on another 150k at .01, then bought more at .05 again on the way back up. I wound up all told with close to 2 mm shares at an average price right around .05 - still hold 75% of them. I don't know how long you guys have been following as I just found this board. After they exited bk, they distributed cash of .35 and then .05 and then .05 again. All to say there are a lot of people sitting on absolutely free shares - which may explain some of the selling you see. I'm not selling the ones I have left. Mgmt did one hell of job administering the estate during bankruptcy - and then they went and didn't do much for the next several years - so at this point I'm 50/50 in my appraisal. From what Driscol told me, Benton was at the time of the merger or acquisition or whatever you want to call it really not an operating entity - it was a concept - which is why they didn't have a whole lot of detail to put into the announcement. It was at the time essentially a group of top researchers at Charles River who were leaving to start up a R&D outsourcing services firm. Benton's target customers would basically be the same pharma's that use D-base mice for research - they saw natural synergies. It was also according to Driscol a biz plan that would not be capital intensive - no long lead times and associated cash requirements for development - they would be getting paid as they went for doing research for others. I would guess given the stage Benton was at when the announcement was made, they are still getting organized - hence not much to report about. DGEN still has a little IP of its own to boot. Driscol wouldn't discuss it, but back at the time when I pretty much bet it all on the line on this company - I followed every lead I could find. My understanding was that there is some frozen research that was some of the best work they ever did that is half finished. Again, completely unconfirmed.
Yep - have noticed - and that 100K at the ask last week - maybe we are close.
We have someone sitting on the bid at .075 who has taken sells of 10,000 and 20,000 so far today. Maybe someone has taken notice of how cheap DGEN is and intends to gradually buy a boatload -- we will see.
Gotta love a $91.00 trade that can bring the stock down 27%!
Satellite - did you ever call the CEO?? Are there any announcements/PRs in the pipeline? As I mentioned in an earlier post, I am happy to make this call. Feel free to PM me with his contact info.
Thanks
Walker--- I don't understand it either. Why would NITE leave with this scenario? Volume was good yesterday after some crappie days--finally. I am doing my taxes and it is making me sick with my losses. I am forming a new strategy for 2010 and it doesn't include the OTC market. With any luck, I will sell today at .075 and be gone. I will probably look up in June and see it has passed .50. Thats the way my luck went in 2009.
Then maybe mine will sell today. Good luck to all but I am leaving the OTC market.
It reminds me a little of what happened the week before they announced the acquisition, when we saw volume out of nowhere and jumped in.
Lets just hope it continues - maybe someone knows something - hopefully!!!
I like it !!!
You see this buying - 100K out of nowhere - interesting
I'm continuing to be patient here. I think we will hear from the company before too long....
hold up - some buying at the ask hitting now - WOW!!!
Mine is getting there as well - still don't see why those 2 funds would pay .162 per share for 1.8 million worth if the company was not worth that or more. I am holding and hoping.
Walker--- Well, my patience is worn thin. I'm gone as soon as the volume goes up enough to sell at all. This is riduculous. I really thought it had potential. I am not so sure now. Maybe there is something about management I don't know, but I hate being in any equity where interest has dried up. No interest = no liquidity!
Could have been me for bringing it up in the 1st place
Well yeah, I guess so, psychically
I think you did
NITE is back, at .0527 x .078. I did not summon him.
No way - good riddance - rather have buying oush this up with no resistance.
Quite the spread, .0526 x .09. I'm trying to decide whether I'd rather see NITE return if they came in at, say, .06 x .08.
Nice buys - .09 ask now
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
333
|
Created
|
12/14/06
|
Type
|
Free
|
Moderators |
Deltagen is a leading provider of drug discovery tools and services to the biopharmaceutical industry. Deltagen offers a suite of programs designed to enhance the efficiency of drug discovery including access to biological models as well as both small-molecule and secreted protein drug targets. In addition, Deltagen offers extensive target validation data in the areas of immunology and metabolic diseases. Deltagen's products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Millennium Pharmaceuticals and Pfizer.
Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology enables us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed. Using our proprietary tools, we believe we can uncover clinically relevant drug targets more efficiently and earlier in the discovery process.
The scientists in our Target Discovery Program have developed methods to discover the gene function of novel drug targets and to understand disease pathways as we strive to accelerate the development of meaningful, commercially promising small-molecule and secreted-protein therapies. Our proprietary technology platforms serve the drug discovery efforts of our pharmaceutical partners and customers.
Snapshot Information
June 27, 2003 Files Chapter 11 BK ~ Lexicon Genetics sues Deltagen over royalties
Nov 15, 2005 Court Approves reorganization
March 14, 2005 Lexicon and Deltagen Settle diputes, Deltagen pays 4Million cash payment
Sept 2005 NIH gives 3 year contract, valued up to $25 Million
Sept 2005 (CRL) Charles River Laboratorys becomes exclusive custodian of world wide distributor of Deltagens repository.
Sept 30 2005 NIH orders $5.16 Million worth of knockout mouse
Nov 15 2005 Court Approves, paying creditor claims 100% and equity preserved intact.
Nov 29 2005 Court Appointed Reorganization effective.
Dec 2005 CEO resigns - Lawrence Hill, VP I&L Robert Driscoll becomes CEO and President and Secretary
Dr. Winston Thomas - elected COO
Dr. Shera Kash - elected VPO
Dr. Driscoll, Mr. Hill, Dr. Chambon, Mr. Hernon - elected to BOD
-----------------------------------------------------------------------------------------------------------------
Jan 2006 NIH pays $1.93 Million
Mar 31 2006 Company closes Chapter 11 BK with all contested claims resolved.
Jan-Feb-Mar ~ brings in $1.8M - 431K net
$1.548M - expenses to salaries, 3rd-party royaty, patent prosecution, legal fees
Cash on hand $10.392 Million.
Jun 30 2006 $3.749 Million Revenue
NIH pays $3.2Million per 3 year contract
$0.500 Million Revenue in Access Fees
$1.4Million Net
Cash on hand $10.789Million
July 2006 Hire investment banking firm to assist strategic alternatives or sale of company.
Sept 30 2006 $0.970 Million Revenue
$0137 net
Cash on hand $11.993Million
Oct 2006 Deltagen enters agreement to 1 time buyout of DeltaBase collborators
Nov 2006 BOD terminate Investment Banking option.
Deltagen moves to new facilities: The Artium, 1900 South Norfolk St. Ste 105, San Mateo, Ca.
Dec 2006 Divy of .20 per share reduces cash by $7.7Million
Cash on hand $4.29Million
Corporate Headquarters
1031 Bing Street
San Carlos, CA 94070
Tel 650-569-5100
New Corporate Headquarters
effective - Jan 1, 2007
The Atrium
1900 South Norfolk Street, Suite 105,
San Mateo, CA 94403.
Products and Programs
Winston Thomas, PhD.
Chief Operating Officer
Tel 650-569-5412
deltaone@deltagen.com
What they do....
Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology enables us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed. Using our proprietary tools, we believe we can uncover clinically relevant drug targets more efficiently and earlier in the discovery process.
Product Line
Since late 2005, Deltagen has had a collaboration with Charles River Laboratories of Wilmington, Massachusetts (NYSE: CRL). Charles River Laboratories, a global provider of solutions that advance the drug discovery and development process for the biopharmaceutical industry, is the exclusive custodian and worldwide distributor of Deltagen's repository of knockout mouse materials
Reference
http://www.criver.com/
Press Releases and Other Information
http://www.deltagen.com/pressreleases/pressreleases.html
OFFICERS
Robert J. Driscoll, J.D., Ph.D.
President and Chief Executive Officer
Robert Driscoll, J.D., Ph.D., President and Chief Executive Officer since 2005, formerly served as the company's Vice President, Intellectual Property & Legal Affairs from 2003 until 2005 and as Associate General Counsel. Prior to joining Deltagen in 1999, Dr. Driscoll was a patent and intellectual property attorney with the law firm of Pillsbury Madison & Sutro LLP. Dr. Driscoll received his Ph.D. in Chemistry from the California Institute of Technology and his J.D. from Loyola Law School. Dr. Driscoll also sits on the company's Board of Directors.
Winston Thomas, Ph.D.
Chief Operating Officer
Winston Thomas, Ph.D., Chief Operating Officer since November 2005, formerly served as the company's Vice President, Scientific Operations from 2003 until November 2005 and as Associate Director and Senior Director of Molecular Biology. Prior to joining Deltagen in 1999, Dr. Thomas was a Senior Scientist at Mercator Genetics, Inc. from 1993 to 1999 and was a postdoctoral fellow at Genentech. Dr. Thomas received his Ph.D. in Cellular and Developmental Biology from Harvard University and his B.Sc. from the University of Utah.
Daniel Ratto
Chief Financial Officer
Daniel Ratto, Chief Financial Officer since 2003, has over 20 years of experience in various financial positions. For the last 16 years, Mr. Ratto has worked as a consultant in the fields of turnarounds, bankruptcy, restructuring, accounting and finance, having worked for a wide variety of companies.
BOARD of DIRECTORS
Constantine E. Anagnostopoulos, Ph.D.
Constantine Anagnostopoulos is Deltagen's Chairman of the Board. Dr. Anagnostopoulos is a retired corporate officer of Monsanto Company, a former managing partner of Gateway Associates, a Missouri-based venture capital firm, and the recently retired lead director of Genzyme Corporation. At Monsanto he served as Director of Research, Head of the New Enterprise Division, General Manager of a number of operating divisions and Chairman, President and CEO of Monsanto Europe-Africa-Middle East. He presently sits on the board of five biopharmaceutical companies, including Dyax Corporation. Dr. Anagnostopoulos received his Ph.D. in Organic Chemistry from Harvard University and is a graduate of the Executive Program in Business Administration of Columbia University. He has served on the Presidential Council on Innovation.
Robert J. Driscoll, J.D., Ph.D.
Robert Driscoll is Deltagen's President, Secretary and Chief Executive Officer. Dr. Driscoll served previously as Deltagen's Vice President, Intellectual Property & Legal Affairs and Associate General Counsel. Prior to joining Deltagen, Dr. Driscoll was a patent and intellectual property attorney with the law firm of Pillsbury Madison & Sutro LLP. Dr. Driscoll received his Ph.D. in Chemistry from the California Institute of Technology and his J.D. from Loyola Law School.
Martin J. Hernon
Marty Hernon is a General Partner of Boston Millenia Partners. From 1994 to 1997, Mr. Hernon was a Principal at Boston Capital Ventures. Previously, he was Assistant General Counsel for Lifetime Corporation, an alternate site healthcare services business, and an attorney in the Business Department at Warner & Stackpole/Kirkpatrick & Lockhart, a Boston law firm. Mr. Hernon received a B.A. in Economics from Boston College, an M.A. in Economics from the University of Maryland and a J.D. from Georgetown University.
Thomas A. Penn, J.D., M.B.A.
Thomas Penn is a Partner of Meridian Venture Partners. From 1998 until 2000 Mr. Penn was a partner of Boston Millennia Partners. From 1994 until 1998, Mr. Penn served as President and Chief Executive Officer of Tektagen, Inc. Prior to joining Tektagen, Mr. Penn was President of Independence Ventures, Inc. Mr. Penn has served as President of the Pennsylvania Biotechnology Association and as Co-Chair of Pennsylvania's Technology 21 Biotechnology Network. Mr. Penn holds B.S. degrees from the Massachusetts Institute of Technology in Metallurgy and Materials Science and in Industrial Management, an M.B.A. from Stanford University, and a J.D. from the University of Pennsylvania.
William A. Scott, Ph.D.
William Scott is the former Chief Executive Officer of Physiome Sciences, where he served from 1997 to 1999. Prior to joining Physiome Sciences, Dr. Scott spent thirteen years with Bristol-Meyers Squibb where he held a number of management posts, including Senior Vice President of Exploratory and Drug Discovery Research. Dr. Scott has served on the boards of eight companies including CombiChem, Inc., and currently serves on the Boards of Atherogenics, Inc. and Avalon Pharmaceuticals, Inc. Dr. Scott holds a B.Sc. in Chemistry from the University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology. Dr. Scott is an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969.
SHARE STRUCTURE - O/S Approx. 39 mil.
DGEN institutional ownership:
2009-11-12 2009-09-30 13F-HR Everett Harris And Co Institution 6,182,188 No Change
http://www.mffais.com/dgen.pk
Top Institutional HoldersConcentration of Current % Held
Everett Harris & Co. 6.2M $494,575 +53% 16.0% Low
Wells Capital ... 5.5M $387,934 +47% 14.4% Moderate
http://data.cnbc.com/quotes/DGEN/tab/8
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6348952
courtesy of Stock Charts:http://stockcharts.com
Disclaimer The members of this board do not recommend that you buy, sell, or hold any of the stocks listed on this board.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |